SG11201911817VA - Checkpoint inhibitor bispecific antibodies - Google Patents

Checkpoint inhibitor bispecific antibodies

Info

Publication number
SG11201911817VA
SG11201911817VA SG11201911817VA SG11201911817VA SG11201911817VA SG 11201911817V A SG11201911817V A SG 11201911817VA SG 11201911817V A SG11201911817V A SG 11201911817VA SG 11201911817V A SG11201911817V A SG 11201911817VA SG 11201911817V A SG11201911817V A SG 11201911817VA
Authority
SG
Singapore
Prior art keywords
bispecific antibodies
checkpoint inhibitor
inhibitor bispecific
checkpoint
antibodies
Prior art date
Application number
SG11201911817VA
Inventor
Michael Kalos
Yiwen Li
Dale Ludwig
Gregory Plowman
Yang Shen
Igor Edmondo Paolo D'angelo
Original Assignee
Lilly Co Eli
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Zymeworks Inc filed Critical Lilly Co Eli
Publication of SG11201911817VA publication Critical patent/SG11201911817VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201911817VA 2017-07-10 2018-07-09 Checkpoint inhibitor bispecific antibodies SG11201911817VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762530436P 2017-07-10 2017-07-10
PCT/US2018/041205 WO2019014091A1 (en) 2017-07-10 2018-07-09 Checkpoint inhibitor bispecific antibodies

Publications (1)

Publication Number Publication Date
SG11201911817VA true SG11201911817VA (en) 2020-01-30

Family

ID=63013165

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911817VA SG11201911817VA (en) 2017-07-10 2018-07-09 Checkpoint inhibitor bispecific antibodies

Country Status (26)

Country Link
US (1) US11203640B2 (en)
EP (1) EP3652216A1 (en)
JP (1) JP6953612B2 (en)
KR (1) KR102309950B1 (en)
CN (1) CN110914306B (en)
AR (1) AR112603A1 (en)
AU (1) AU2018301326B2 (en)
BR (1) BR112020000162A2 (en)
CA (1) CA3069254C (en)
CL (1) CL2020000053A1 (en)
CO (1) CO2019015100A2 (en)
CR (1) CR20190576A (en)
EA (1) EA201992757A1 (en)
IL (1) IL271347B2 (en)
JO (1) JOP20200003B1 (en)
MA (1) MA49563A (en)
MX (1) MX2020000242A (en)
MY (1) MY195071A (en)
NZ (1) NZ760683A (en)
PE (1) PE20200297A1 (en)
PH (1) PH12020500075A1 (en)
SG (1) SG11201911817VA (en)
TW (1) TWI714864B (en)
UA (1) UA126032C2 (en)
WO (1) WO2019014091A1 (en)
ZA (1) ZA201908549B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11498977B2 (en) 2016-09-29 2022-11-15 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
EP3533804A4 (en) 2016-11-18 2020-06-17 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
KR102629905B1 (en) * 2017-04-01 2024-01-30 베이징 한미 파마슈티컬 컴퍼니 리미티드 Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
WO2019153200A1 (en) 2018-02-08 2019-08-15 北京韩美药品有限公司 Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
TWI760751B (en) * 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit and pd-1/tigit-binding molecules
US11083705B2 (en) * 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
TW202130367A (en) * 2020-01-15 2021-08-16 大陸商信達生物製藥(蘇州)有限公司 Preparation and use of bispecific antibodies binding pd-1 and pd-l1
WO2021213523A1 (en) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 Uses of combination of anti-pd-1 antibody and anti-ctla-4 antibody in preventing or treating cancer
WO2021226984A1 (en) * 2020-05-15 2021-11-18 三生国健药业(上海)股份有限公司 Tetravalent bispecific antibody against pd-1 and pd-l1
JP2023116826A (en) * 2020-05-20 2023-08-23 中外製薬株式会社 antigen binding molecule
CN113754773A (en) * 2020-06-02 2021-12-07 三生国健药业(上海)股份有限公司 Bispecific antibody for resisting PD1 XPDL 1
US11865082B2 (en) 2020-09-09 2024-01-09 Hoffmann-La Roche Inc. Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
CN114601924A (en) * 2020-12-09 2022-06-10 信达生物制药(苏州)有限公司 Methods of treating squamous non-small cell lung cancer with anti-PD-1 antibodies or antigen-binding fragments thereof
WO2023020315A1 (en) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 Antibody targeting pd-l1/pd-1 and use thereof
CN118103067A (en) * 2021-09-14 2024-05-28 信达生物制药(苏州)有限公司 Pharmaceutical combinations of anti-PD-1 antibodies and chemotherapeutic agents and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2288600C (en) 1997-05-02 2010-06-01 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
ES2592271T3 (en) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Polypeptide production methods by regulating the association of polypeptides
AR060070A1 (en) 2006-03-24 2008-05-21 Merck Patent Gmbh HETERODYMERIC PROTEIN DOMAINS OBTAINED BY ENGINEERING
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US20130017199A1 (en) * 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
AU2010343057B2 (en) 2009-12-29 2017-02-23 Aptevo Research And Development Llc Heterodimer binding proteins and uses thereof
MX341925B (en) 2010-03-29 2016-09-07 Zymeworks Inc Antibodies with enhanced or suppressed effector function.
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
JP5937077B2 (en) 2010-09-24 2016-06-22 ザイムワークス,インコーポレイテッド Molecular packing calculation system
AU2011308042B2 (en) 2010-09-30 2015-07-16 Zymeworks Inc. Simplifying residue relationships in protein design
BR112013011811A2 (en) 2010-11-05 2023-02-23 Zymeworks Inc STABLE HETERODIMERIC ANTIBODY MODEL WITH MUTATIONS IN THE FC DOMAIN
WO2012116453A1 (en) 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
RS62689B1 (en) 2011-11-04 2021-12-31 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
LT2794905T (en) 2011-12-20 2020-07-10 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
KR102382304B1 (en) 2012-04-20 2022-04-04 메뤼스 엔.페. Methods and means for the production of ig-like molecules
EP2847224A4 (en) 2012-05-10 2016-04-27 Zymeworks Inc Single-arm monovalent antibody constructs and uses thereof
CA2872540A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
US20140154253A1 (en) 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
CA2878587A1 (en) 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
WO2014055784A1 (en) 2012-10-03 2014-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
CA2889951C (en) 2012-11-02 2023-04-18 Zymeworks Inc. Crystal structures of heterodimeric fc domains
KR102264570B1 (en) 2012-11-28 2021-06-14 자임워크스 인코포레이티드 Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2015109131A2 (en) 2014-01-15 2015-07-23 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
JOP20200094A1 (en) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
EP3107938B1 (en) 2014-05-28 2022-05-04 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
UY36351A (en) * 2014-10-14 2016-06-01 Novartis Ag ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME
JP6840127B2 (en) * 2015-07-29 2021-03-10 ノバルティス アーゲー Combination of anti-PD-1 antibody and anti-M-CSF antibody in the treatment of cancer
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (en) * 2015-08-24 2017-10-25 Lilly Co Eli ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH)
US20180346571A1 (en) 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof

Also Published As

Publication number Publication date
WO2019014091A1 (en) 2019-01-17
CN110914306B (en) 2023-06-02
PH12020500075A1 (en) 2020-11-09
ZA201908549B (en) 2021-08-25
KR102309950B1 (en) 2021-10-08
NZ760683A (en) 2023-02-24
CR20190576A (en) 2020-03-03
PE20200297A1 (en) 2020-02-06
JOP20200003A1 (en) 2020-01-07
JP6953612B2 (en) 2021-10-27
CA3069254A1 (en) 2019-01-17
MY195071A (en) 2023-01-08
CL2020000053A1 (en) 2020-10-30
MX2020000242A (en) 2020-08-10
UA126032C2 (en) 2022-08-03
AR112603A1 (en) 2019-11-20
CN110914306A (en) 2020-03-24
CA3069254C (en) 2023-09-12
IL271347A (en) 2020-01-30
TWI714864B (en) 2021-01-01
US11203640B2 (en) 2021-12-21
TW201920263A (en) 2019-06-01
JOP20200003B1 (en) 2023-03-28
IL271347B1 (en) 2023-12-01
EP3652216A1 (en) 2020-05-20
KR20200021982A (en) 2020-03-02
IL271347B2 (en) 2024-04-01
AU2018301326B2 (en) 2021-05-13
CO2019015100A2 (en) 2020-04-24
US20190010232A1 (en) 2019-01-10
EA201992757A1 (en) 2020-04-27
MA49563A (en) 2020-05-20
JP2020527136A (en) 2020-09-03
BR112020000162A2 (en) 2020-07-14
AU2018301326A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
IL263542A (en) Bispecific checkpoint inhibitor antibodies
ZA201908549B (en) Checkpoint inhibitor bispecific antibodies
HK1256365A1 (en) Bispecific antibodies specific for pd1 and tim3
PL3519437T3 (en) Bispecific antibodies against p95her2
IL279235A (en) Dll3-cd3 bispecific antibodies
IL269002A (en) Antibodies against pd-l1
IL267797B1 (en) Anti-gpc3 antibody
GB201709808D0 (en) Antibodies
GB201710838D0 (en) Bispecific antibodies
GB201707561D0 (en) GARP-TGF-beta antibodies
ZA202004908B (en) Bispecific antibody
IL271832A (en) Bispecific anti pd1-anti tim3 antibodies
HK1250046A1 (en) Anti-dkk-1-anti-rankl bispecific antibody compounds
IL269577B (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
IL282355A (en) Exosome-targeting bispecific antibodies
IL273529A (en) Anti-pacap antibody
EP3693013A4 (en) Bispecific antibody
IL286918A (en) Bispecific antibody
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
IL290050A (en) Bispecific antibody
IL272676B (en) Anti-il4-il 13 bispecific antibodies
GB201711785D0 (en) Antibodies
GB201511196D0 (en) Monoclonal antibodies
GB201709592D0 (en) Antibody
GB201709818D0 (en) Antibodies